Analysts’ Viewpoint on Pharmacovigilance (PV) Market Scenario
The global pharmacovigilance industry is growing cumulatively, as it is driven by increase in awareness within the public health sector coupled with rise in preference for safe medicines. This service is helping in surveillance of expected or unexpected effects that may appear or may be aggravated due to potential combination of drugs amid the ongoing COVID-19 pandemic. As such, the market for pharmacovigilance is anticipated to thrive at a significant CAGR during the years 2021 to 2028. Globally, the growing number of national pharmacovigilance centers is playing an imperative role to support the growth of the market over the next few years. Needless to mention, pharmacovigilance is witnessing numerous challenges to develop a better healthcare system. The unavailability of skilled labor and information about drugs obtained via the web could be two high-impact restraints of the market. However, rigorous pharmacovigilance activities that could be made compulsory are expected to fuel the demand for services in the market. Such mandatory activities help to actively manage high-risk medicines.
Stakeholders in the pharmacovigilance market are extending their services in preclinical studies, and clinical trial phases I, II, III, and IV by phase of drug development. Phase IV a.k.a. post-marketing surveillance has contributed to a large share in terms of revenue in the previous years. Safety worries relating to marketed products, the growing necessity of designing systems to compare safety profiles of homologous medicinal products, and rising public health awareness campaigns are a few of the reasons contributing to the growth of the pharmacovigilance (PV) market.
Clinical trial phase III is predicted to set to rise at a high growth rate due to the escalating need for monitoring of drug safety. This phase emphasizes drug safety and efficiency in diverse sub-groups, where the benefit-risk ratio is developed, scrutinized, and updated accordingly. In order to be more accurate on the part of drug safety, biopharmaceutical companies are focusing on creating advanced clinical trial phases.
To know the scope of our report Get a Sample of the Pharmacovigilance Market
The need for pharmacovigilance services has increased due to the COVID-19 pandemic. Companies in the market for pharmacovigilance are taking advantage of this opportunity by increasing awareness about Coronavirus vaccine safety guidance. Information on each of the authorized vaccines, including authorization, manufacturing, and dosage, among other details, is fuelling the demand for pharmacovigilance services. This information is presented in layers, which allow sequential access to degrees of increasing depth of information. At the same time, pharmacovigilance monitoring of COVID-19 patients has become an international priority. Healthcare organizations are encouraging this activity in an attempt to guarantee health transparency.
Get a glimpse of the in-depth analysis through our Report Brochure
The pharmacovigilance (PV) market is anticipated to grow at a promising rate due to the increasing demand for contract outsourcing and in-house pharmacovigilance. An important factor helping with the growth of contract outsourcing could be a shift in focus to core business activities from that non-core by outsourcing pharmacovigilance services. This will lead to a decrease in operational and financial costs suffered from delays in product approval.
The global pharmacovigilance market is positioned for a healthy growth rate throughout the assessment period. Intensified ADR (Adverse Drug Reaction) reporting, targeted spontaneous reporting, and cohort event monitoring activities are providing impetus to market growth. During recent years, in terms of revenue, the use of spontaneous reporting methods is growing at a rapid pace since it is a more accurate technique for discovering new ADRs.
Expanding operations in the future? To get the perfect launch to ask for a custom report
Asia Pacific is expected to gain high growth during the forecast period. Factors supporting market growth in this region are envisaged to include high demand for strict healthcare regulations and an increase in the number of clinical trials being set up. Nevertheless, developed regions are projected to significantly contribute to the pharmacovigilance market. For instance, North America’s cost-benefit gained by switching to contract research organization (CRO) outsourcing from expensive in-house activities are projected to help the region to collect a larger revenue share of the market.
Increased death rates due to adverse drug reactions and a rise in patient fears regarding the safety of medicinal products have propelled the North American market for pharmacovigilance in recent years. A report by the Centers for Disease Control and Prevention (CDC) states that there are around several thousand deaths caused by ADRs in the U.S., which are counted among the top 10 leading causes of death in the country.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 6.1 Bn |
|
Market Forecast Value in 2028 |
US$ 11.5 Bn |
|
Growth Rate (CAGR) |
8.8% (Year-on-Year) |
|
Forecast Period |
2021–2028 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross-segment and regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Pharmacovigilance Market – Segmentation
| Drug Development |
|
| Type of Methods |
|
| Type of Service |
|
| Region |
|
The global market for pharmacovigilance was worth US$ 6.1 Bn and is projected to reach a value of US$ 11.5 Bn by the end of 2028
The pharmacovigilance market is anticipated to grow at a CAGR of 8.8% during the forecast period
North America accounted for a major share of the global pharmacovigilance market
The pharmacovigilance (PV) market is growing cumulatively, as it is driven by an increase in awareness within the public health sector coupled with rise in preference for safe medicines
Key players in the global pharmacovigilance industry include Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant, Labcorp Drug Development, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, ICON plc, iGATE Corporation, iMEDGlobal Corporation, Syneos Health, Novartis AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), IQVIA, Sanofi, Synowledge LLC, and Wipro Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmacovigilance Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. COVID-19 Impact on the Pharmacovigilance Market
5.2. Technological Advancements (big data analytics, cloud-based database, automation)
5.3. Drugs Regulatory Framework of Pharmacovigilance Market
5.4. Pharmacovigilance Market: Value Chain Analysis
5.5. Pharmacovigilance Market: Porter’s Five Forces Analysis
5.6. Overview of Drugs Adverse Effects
6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017–2028
6.2.1. Preclinical Studies
6.2.2. Phase I
6.2.3. Phase II
6.2.4. Phase III
6.2.5. Phase IV or Post Marketing Surveillance
6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017–2027
7.2.1. Spontaneous Reporting
7.2.2. Intensified ADR Reporting
7.2.3. Targeted Spontaneous Reporting
7.2.4. Cohort Event Monitoring
7.2.5. EHR Mining
7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028
8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017–2027
8.2.1. In-house
8.2.2. Contract Outsourcing
8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
9. Global Pharmacovigilance Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Pharmacovigilance Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
10. North America Pharmacovigilance Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
10.2.1. Preclinical Studies
10.2.2. Phase I
10.2.3. Phase II
10.2.4. Phase III
10.2.5. Phase IV or Post Marketing Surveillance
10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
10.3.1. Spontaneous Reporting
10.3.2. Intensified ADR Reporting
10.3.3. Targeted Spontaneous Reporting
10.3.4. Cohort Event Monitoring
10.3.5. EHR Mining Others
10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
10.4.1. In-house
10.4.2. Contract Outsourcing
10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
10.6.1. By Phase of Drug Development
10.6.2. By Type of Method
10.6.3. By Type of Service
10.6.4. By Country
11. Europe Pharmacovigilance Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
11.2.1. Preclinical Studies
11.2.2. Phase I
11.2.3. Phase II
11.2.4. Phase III
11.2.5. Phase IV or Post Marketing Surveillance
11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
11.3.1. Spontaneous Reporting
11.3.2. Intensified ADR Reporting
11.3.3. Targeted Spontaneous Reporting
11.3.4. Cohort Event Monitoring
11.3.5. EHR Mining
11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
11.4.1. In-house
11.4.2. Contract Outsourcing
11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028
11.6.1. By Phase of Drug Development
11.6.2. By Type of Method
11.6.3. By Type of Service
11.6.4. By Country/Sub-region
12. Asia Pacific Pharmacovigilance Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
12.2.1. Preclinical Studies
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.2.5. Phase IV or Post Marketing Surveillance
12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
12.3.1. Spontaneous Reporting
12.3.2. Intensified ADR Reporting
12.3.3. Targeted Spontaneous Reporting
12.3.4. Cohort Event Monitoring
12.3.5. EHR Mining
12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
12.4.1. In-house
12.4.2. Contract Outsourcing
12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028
12.6.1. By Phase of Drug Development
12.6.2. By Type of Method
12.6.3. By Type of Service
12.6.4. By Country/Sub-region
13. Latin America Pharmacovigilance Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
13.2.1. Preclinical Studies
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.2.5. Phase IV or Post Marketing Surveillance
13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
13.3.1. Spontaneous Reporting
13.3.2. Intensified ADR Reporting
13.3.3. Targeted Spontaneous Reporting
13.3.4. Cohort Event Monitoring
13.3.5. EHR Mining
13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
13.4.1. In-house
13.4.2. Contract Outsourcing
13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
13.6.1. By Phase of Drug Development
13.6.2. By Type of Method
13.6.3. By Type of Service
13.6.4. By Country/Sub-region
14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
14.2.1. Preclinical Studies
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.2.5. Phase IV or Post Marketing Surveillance
14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
14.3.1. Spontaneous Reporting
14.3.2. Intensified ADR Reporting
14.3.3. Targeted Spontaneous Reporting
14.3.4. Cohort Event Monitoring
14.3.5. EHR Mining
14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
14.4.1. In-house
14.4.2. Contract Outsourcing
14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028
14.6.1. By Phase of Drug Development
14.6.2. By Type of Method
14.6.3. By Type of Service
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share / Position Analysis, by Company, 2020
15.3. Competitive Business Strategies
15.4. Company Profiles
15.4.1. Accenture plc
15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.1.2. Phase of Drug Development Portfolio
15.4.1.3. Financial Overview
15.4.1.4. Strategic Overview
15.4.1.5. SWOT Analysis
15.4.2. Bristol-Myers Squibb
15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.2.2. Phase of Drug Development Portfolio
15.4.2.3. Financial Overview
15.4.2.4. Strategic Overview
15.4.2.5. SWOT Analysis
15.4.3. Clinquest Group B.V.
15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.3.2. Phase of Drug Development Portfolio
15.4.3.3. Financial Overview
15.4.3.4. Strategic Overview
15.4.3.5. SWOT Analysis
15.4.4. Cognizant
15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.4.2. Phase of Drug Development Portfolio
15.4.4.3. Financial Overview
15.4.4.4. Strategic Overview
15.4.4.5. SWOT Analysis
15.4.5. Labcorp Drug Development
15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.5.2. Phase of Drug Development Portfolio
15.4.5.3. Financial Overview
15.4.5.4. Strategic Overview
15.4.5.5. SWOT Analysis
15.4.6. F. Hoffmann-La Roche Ltd.
15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.6.2. Phase of Drug Development Portfolio
15.4.6.3. Financial Overview
15.4.6.4. Strategic Overview
15.4.6.5. SWOT Analysis
15.4.7. GlaxoSmithKline plc
15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.7.2. Phase of Drug Development Portfolio
15.4.7.3. Financial Overview
15.4.7.4. Strategic Overview
15.4.7.5. SWOT Analysis
15.4.8. ICON plc
15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.8.2. Phase of Drug Development Portfolio
15.4.8.3. Financial Overview
15.4.8.4. Strategic Overview
15.4.8.5. SWOT Analysis
15.4.9. iGATE Corporation
15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.9.2. Phase of Drug Development Portfolio
15.4.9.3. Financial Overview
15.4.9.4. Strategic Overview
15.4.9.5. SWOT Analysis
15.4.10. iMEDGlobal Corporation
15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.10.2. Phase of Drug Development Portfolio
15.4.10.3. Strategic Overview
15.4.10.4. SWOT Analysis
15.4.11. Syneos Health
15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.11.2. Phase of Drug Development Portfolio
15.4.11.3. Financial Overview
15.4.11.4. Strategic Overview
15.4.11.5. SWOT Analysis
15.4.12. Novartis AG
15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.12.2. Phase of Drug Development Portfolio
15.4.12.3. Financial Overview
15.4.12.4. Strategic Overview
15.4.12.5. SWOT Analysis
15.4.13. PAREXEL International Corporation
15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.13.2. Phase of Drug Development Portfolio
15.4.13.3. Financial Overview
15.4.13.4. Strategic Overview
15.4.13.5. SWOT Analysis
15.4.14. Pfizer, Inc.
15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.14.2. Phase of Drug Development Portfolio
15.4.14.3. Financial Overview
15.4.14.4. Strategic Overview
15.4.14.5. SWOT Analysis
15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)
15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.15.2. Phase of Drug Development Portfolio
15.4.15.3. Financial Overview
15.4.15.4. Strategic Overview
15.4.15.5. SWOT Analysis
15.4.16. IQVIA
15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.16.2. Phase of Drug Development Portfolio
15.4.16.3. Financial Overview
15.4.16.4. Strategic Overview
15.4.16.5. SWOT Analysis
15.4.17. Sanofi
15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.17.2. Phase of Drug Development Portfolio
15.4.17.3. Financial Overview
15.4.17.4. Strategic Overview
15.4.17.5. SWOT Analysis
15.4.18. Synowledge LLC
15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.18.2. Phase of Drug Development Portfolio
15.4.18.3. Strategic Overview
15.4.18.4. SWOT Analysis
15.4.19. Wipro Limited
15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.19.2. Phase of Drug Development Portfolio
15.4.19.3. Financial Overview
15.4.19.4. Strategic Overview
15.4.19.5. SWOT Analysis
List of Tables
Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017–2028
Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017–2028
Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
List of Figures
Figure 01: Pharmacovigilance Market Snapshot
Figure 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027
Figure 03: Market Value Share, by Phase of Drug Development, 2018
Figure 04: Market Value Share, by Type of Service, 2018
Figure 05: Market Value Share, by Region, 2018
Figure 06: Global Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Preclinical Studies, 2017–2028
Figure 08: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase I, 2017–2028
Figure 09: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase II, 2017–2028
Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase III, 2017–2028
Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase IV or Post Marketing Surveillance, 2017–2028
Figure 12: Global Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Phase of Drug Development
Figure 13: Global Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), Spontaneous Reporting, 2017–2028
Figure 15: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intensified ADR Reporting, 2017–2028
Figure 16: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Spontaneous Reporting, 2017–2028
Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cohort Event Monitoring, 2017–2028
Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EHR Mining, 2017–2028
Figure 19: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2028
Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 21: Global Pharmacovigilance Market Value Share Analysis, by Type of Service Providers, 2020 and 2028
Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2017–2028
Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsourcing, 2017–2028
Figure 24: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 25: Global Pharmacovigilance Market Value Share Analysis, by Region, 2020 and 2028
Figure 26: Global Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
Figure 27: North America Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028
Figure 28: North America Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
Figure 29: North America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 30: North America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 31: North America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
Figure 32: North America Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
Figure 33: North America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
Figure 34: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 35: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 36: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028
Figure 37: Europe Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
Figure 38: Europe Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 39: Europe Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 40: Europe Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
Figure 41: Europe Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
Figure 42: Europe Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
Figure 43: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 44: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 45: Asia Pacific Pharmacovigilance Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017– 2028
Figure 46: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Country 2021–2028
Figure 47: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 48: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 49: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
Figure 50: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Country, 2018 and 2027
Figure 51: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
Figure 52: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 53: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 54: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028
Figure 55: Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Country/Sub-region, 2021–2028
Figure 56: Latin America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 57: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 58: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
Figure 59: Latin America Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
Figure 60: Latin America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
Figure 61: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 62: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 63: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, 2017–2028
Figure 64: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
Figure 65: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
Figure 66: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
Figure 67: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
Figure 68: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
Figure 69: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
Figure 70: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
Figure 71: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
Figure 72: Global Pharmacovigilance Market Share Analysis, by Company (2020)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pharmacovigilance Market
*86 figures and 60 tables includes